MicroRNA 122 (miR-122) stimulates the replication and translation of hepatitis C virus (HCV) RNA by binding to two adjacent sites, S1 and S2, within the HCV 5¢UTR. We demonstrated previously that the miR-122 antagomir miravirsen (SPC3649) suppresses the infection of HCV strain JFH1-based recombinants with HCV genotypes 1-6 5¢UTR-NS2 in human hepatoma Huh7.5 cells. However, specific S1 mutations were permitted and conferred virus resistance to miravirsen treatment. Here, using the J6 (genotype 2a) 5¢UTR-NS2 JFH1-based recombinant, we performed reverse-genetics analysis of S1 (ACACUCCG, corresponding to miR-122 seed nucleotide positions 8-1), S2 (CACUCC, positions 7-2), and ACCC (positions 1-4) at the 5¢ end of the HCV genome (5¢E); the CC at positions 2-3 of 5¢E is involved in miR-122 binding. We demonstrated that the 5¢E required four nucleotides for optimal function, and that G or A at position 3 or combined GA at positions 2-3 of 5¢E was permitted. In S1 and S2, several single mutations were allowed at specific positions. A UCC fi CGA change at positions 4-3-2 of S1, S2, or both S1 and S2 (S1/S2), as well as a C fi G change at position 2 of S1/S2 were permitted. We found that 5¢E mutations did not confer virus resistance to miravirsen treatment. However, mutations in S1 and S2 induced virus resistance, and combined S1 and/or S2 mutations conferred higher resistance than single mutations. Identification of miR-122 antagomir resistance-associated mutations will facilitate the study of additional functions of miR-122 in the HCV life cycle and the mechanism of virus escape to host-targeting antiviral approaches.
INTRODUCTION
Hepatitis C virus (HCV) persistently infects over 150 million people worldwide and is a leading cause of end-stage chronic liver diseases, including liver cirrhosis and cancer (Alter & Seeff, 2000; Bukh et al., 1993) . HCV belongs to genus Hepacivirus in the family Flaviviridae, and the HCV genome is a positive-sense ssRNA of~9.6 kb, with a relatively high heterogeneity among isolates (Gottwein & Bukh, 2008; Moradpour et al., 2007) . According to differences in nucleotide and amino acid sequences, HCV isolates are classified into seven major genotypes differing by~30 % in their genome sequences, and subclassified into numerous subtypes with sequence heterogeneity of 15-20 % (Smith et al., 2014) . The virus exists as a heterogeneous quasispecies in infected individuals with implications for escape from host immune responses and antivirals (Farci et al., 1997; Forns et al., 1999) . The HCV genome consists of a single ORF flanked by 5¢ and 3¢ UTRs. The ORF is translated into a single polyprotein, which is processed by viral and cellular proteases into 10 structural and non-structural (NS) proteins (Gottwein & Bukh, 2008; Moradpour et al., 2007) . Until recently, efficient HCV infectious culture systems were based on the genotype 2a isolate JFH1 in systems permitting studies in vitro and in vivo (Bukh, 2012; (nt 1-42; numbering according to genotype 2a isolate HC-J6, GenBank accession no. NC_009823) contains one stemloop structure (stem-loop I, SLI) (Honda et al., 1999) , and two microRNA 122 (miR-122) binding sites (S1 and S2) (Henke et al., 2008; Jopling, 2008; Jopling et al., 2005; Machlin et al., 2011) . It has been shown that the SLI is important for viral RNA replication (Friebe et al., 2001; Luo et al., 2003) , and we demonstrated that it is essential for the viability of infectious HCV genotype 1-6 recombinants (Li et al., 2011a) . miR-122 is a liver-abundant miRNA (Chang et al., 2004) , and it stimulates viral RNA replication and translation by directly binding to S1 and S2, as well as to upstream nucleotides, in the HCV 5¢UTR (Fig. 1a) (Henke et al., 2008; Jopling, 2008; Jopling et al., 2005; Machlin et al., 2011) . miR-122 binds HCV RNA in association with Ago2, thus stabilizing the viral RNA (Shimakami et al., 2012) and protecting the 5¢ end of the viral RNA from degradation by Xrn1 (Li et al., 2013) .
The drug miravirsen (SPC3649) is a b-D-oxy-locked nucleic acid (LNA)-modified phosphorothioate antisense oligonucleotide targeting miR-122 (Elm en et al., 2008) . Miravirsen can mediate efficient inhibition of miR-122 function in liver cells when transfected at low nanomolar concentrations (Elm en et al., 2008) . Recently, we demonstrated that infection of HCV genotypes 1-6 in cultured cells was inhibited by miravirsen-mediated antagonism of miR-122 (Li et al., 2011a) . Other studies have shown that miR-122 antagonism efficiently suppresses HCV genotype 1a and 1b chronic infection in chimpanzees, with no evidence of virus resistance (Lanford et al., 2010) . In a clinical phase II trial, miravirsen showed long-lasting dose-dependent suppression of viraemia in chronic HCV genotype 1-infected patients, without evidence of virus resistance (Janssen et al., 2013) , thus showing its potential as a host-targeting antiviral drug for HCV therapy.
We demonstrated previously that introduction of selected mutations in the miR-122 binding site S1 conferred virus resistance to miravirsen treatment in cell culture (Li et al., 2011a) ; subsequent studies identified virus resistant to miravirsen treatment (Israelow et al., 2014; Ottosen et al., 2015) . These observations indicate that HCV therapy using miR-122 antagomirs would also encounter the issue of virus escape. However, it is unknown whether other nucleotides in miR-122 S1 and S2 are permissive for infectious culture and could potentially confer resistance to antagomir therapy. In this study, we performed a systematic reverse-genetics analysis of S1 and S2 and the first four nucleotides upstream of SLI, which contains nucleotides involved in miR-122 binding. We identified permissive mutations in the miR-122 binding nucleotides and mutant viruses resistant to miravirsen treatment. Our findings provide novel miR-122-independent mutant viruses, which will facilitate the study of the mechanism of virus escape to host-targeting approaches and of miR-122-independent HCV replication.
RESULTS
Mutations at miR-122 auxiliary binding nucleotides at the 5¢ end of the HCV genome do not confer virus resistance to miravirsen At the 5¢ end (5¢E) of genotype 2a strain J6, there are four nucleotides, ACCC (positions 1-4) upstream of the SLI, of which CC at positions 2-3 appears to be involved in miR-122 binding (Fig. 1a) (Machlin et al., 2011) . We previously found that deletion of the first nucleotide, A, of the J6 5¢UTR-NS2 /JFH1 recombinant could be repaired by addition of A or AC at the 5¢ terminus during virus replication in Huh7.5 cells, thus producing viruses with a variable length of 5¢E upstream of SLI (Li et al., 2011a, b) . To further study the CC at positions 2-3, we generated J6 5¢UTR-NS2 /JFH1 with deletion of nucleotides at positions 1-2 (designated D1-2), 1-4 (D1-4) and 2-3 (D2-3), as well as nucleotide deletions plus specific mutations: C2U/D3-4 (C at position 2 changed to U, plus D3-4) and C3U/D4. In addition, we constructed recombinants with C2 and C3 individually mutated to A, U or G, and ones with an additional C or CC inserted after the first A, designated InsC and InsCC, respectively (Table 1) . The viability of the mutants was tested by RNA transfection of Huh7.5 cells and subsequently following the transfection culture to allow virus spread to ! 80 % cells (referred to as 'peak infection'); wild-type (WT) recombinant J6 5¢UTR-NS2 / JFH1 was included in parallel as a positive control. The WT recombinant infected 50-80 % of cells on day 1 post-transfection, whereas all the 5¢E mutants were attenuated. C2U/ D3-4 and D1-4 were non-viable after 29 days of follow-up, D1-2 culture was not HCV positive until day 4, and the D2-3 culture showed evidence of HCV infection on day 1 with a few positive cells. The remaining 5¢E mutants showed 5-20 % HCV-infected cells on day 1 (Table 1) .
Transfection culture supernatants were collected at peak infection and inoculated onto naïve Huh7.5 cells to produce first-passage virus and subsequently second-passage virus, if the introduced mutation was maintained or the recovered virus acquired additional changes in the first passage (Table 1) . To determine the consensus sequence of passagerecovered viruses, reverse transcription (RT)-PCR products of 5¢RACE were directly sequenced, unless otherwise stated. C2A and C2G mutants reverted to WT in the first passage, whereas C2U was maintained in the first passage, but reverted in the second passage. C3U reverted in the first passage, while C3A and C3G were maintained after the first and second passages. C3U/D4 acquired a C insertion at position 2 (in three out of seven amplicon clones) in the first passage, and the population with the C insertion became dominant in the second passage determined by consensus sequencing. InsC was partially reverted in the first passage and completely reverted in the second passage. One C was deleted from InsCC in both passages, and GA was inserted in D2-3 in both passages (Fig. 1b and Table 1 ). Recombinant D1-2 reverted to the WT sequence in the first passage.
As the first-passage D2-3 virus acquired GA at positions 2-3 of the genome, replacing the original CC involved in miR-122 binding, we constructed a recombinant resembling this sequence, with AGA as nt 1-3 of the 5¢E (designated C2G/ C3A). C2G/C3A showed 10 % HCV infection on day 1 post-transfection and maintained the engineered nucleotides after the first and second passages; thus, its sequence was identical to passage-recovered D2-3 (Table 1) . Titration of the different viruses that maintained mutations after the second passage revealed that HCV infectivity titres were 10 4.5 -10 5.3 focus-forming units (f.f.u.) ml
À1
, comparable to that of the control J6 5¢UTR-NS2 /JFH1. Taken together, HCV was able to repair the mutated 5¢E by acquiring (or deleting) additional nucleotides to maintain a specific length, optimally 4 nt (ACCC in the genotype 2a Machlin et al. (2011) . (b) Permissive mutations identified in second-passage viruses in this study are shown in red and aligned with the nucleotides of the original HCV sequence; single mutations are shown individually, combined mutations in S1 or S2 are underlined, combined mutations in S1 and S2 are indicated by a connecting dotted line, a dash indicates a deletion of the nucleotide corresponding to the aligned original sequence, and the arrow indicates a nucleotide insertion. U4C in S1 was from our previous study (Li et al., 2011a) . (c) The Cell-U3 recombinant with a small nucleolar RNA (snoRNA) U3 insertion. The G identified from second-passage Cell-U3 virus was engineered into the genome to generate Cell-U3/InsG. (d) Single or combined mutations conferring virus resistance to miravirsen treatment are indicated in red, as described in (b). In the treatment assays, the infection rate of WT control virus was generally < 20 %, and thus mutants with ! 20 % HCV infection were considered resistant; mutations tested previously are shown in purple (Li et al., 2011a) , while those tested in this study are shown in red. (e, f) Nucleotide composition of the mutants S1_A8G+S1S2m and S1_A8C+S1S2m; 'm' indicates S1S2_432CGA and DGCCAU; '-' indicates nucleotide deletion. /JFH1 virus was not passaged in this study. However, no mutations were found in the 5¢UTR sequence after virus passage in previous studies (Li et al., 2011a) . genome). A single mutation replacing the C at position 2 (C2) was not permissible or was genetically unstable, while A or G replacing the C at position 3 (C3), or combined GA at positions 2-3 was permitted for efficient infectious culture (Fig. 1b) .
To study whether the mutations within the 5¢E conferred virus resistance to miravirsen-mediated miR-122 antagonism, we transfected Huh7.5 cells with miravirsen and then infected the cells with HCV mutants as described previously (Li et al., 2011a) . A recombinant with a U3 RNA insertion replacing the SLI and miR-122 binding site 1 (named Cell-U3), shown previously to be highly resistant to miravisen treatment (Li et al., 2011a) , was used as a control (Fig. 1c) . In the treatment assays, HCV infection in the mock infection was arbitrarily defined as 100 %. As shown in Fig. 2(a) , all the viruses with mutations within the 5¢E were inhibited by miravirsen in a dose-dependent manner. The inhibition was similar to the levels seen for WT J6 5¢UTR-NS2 /JFH1 at different doses. At a dose of 0.4 nM miravirsen, < 3 % HCV infection was found for 5¢E-mutated viruses compared with the mock infection, and was similar to the 6 % observed for the WT virus, whereas Cell-U3 virus produced~70 % HCV infection. These results indicated that the permissive mutations in the 5¢E region, including nucleotides involved in miR-122 binding, did not confer virus resistance to the antiviral effect of miR-122 antagonism.
Permissive point mutations in the miR-122 binding site S1 or S2 of HCV confer partial virus resistance to miR-122 antagonism
We demonstrated previously that miR-122 S1 permitted mutations identified from the nucleotides in the U3 RNA insertion, and that the S1 mutants conferred virus resistance to miravirsen treatment to different extents (Li et al., 2011a) . To study the viability of 2a recombinants with other mutations in S1, we mutated each nucleotide of the S1 sequence (ACACUCCG, corresponding to the miR-122 seed nucleotide positions 8-1) with the other two nucleotides not tested previously (Table 2) (Li et al., 2011a) . As combination of two mutations was permitted in S1 nt 4-1 (Li et al., 2011a) , we also constructed recombinants with double mutations at positions 6 and 5, designated S1_A6G/ C5U, and at positions 4 and 3, designated S1_U4A/C3G (Table 2 ). After RNA transfection of Huh7.5 cells, all S1 mutant recombinants were viable; however, those with mutations at positions 7, 6, 5, 4 or 3, or with double mutations, had fewer HCV-positive cells (1-10 %) on day 1 (Table 2) . Virus from peak infection of transfection cultures was passaged to naïve Huh7.5 cells, and sequence analysis of first-passage viruses revealed that only recombinants with S1 mutations A8U, A8C, U4G, C2G, G1C or U4A/ C3G maintained the engineered mutations, whereas those with U4A, C3U or C2U partially reverted, and the remaining mutants all reverted to the original WT sequence (Table 2 ). We performed a second passage for S1 mutants with A8U, A8C, U4A, U4G, C2G, G1C and U4A/C3G viruses, and only S1_C2G and S1_G1C viruses maintained the mutations, producing HCV infectivity titres of 10 4.2 and 10 4.6 f.f.u. ml
, respectively (Table 2) . Thus, we concluded that each of the S1 positions 8, 7, 6 and 5 did not permit other nucleotides, whereas positions 4, 3, 2 and 1 permitted nucleotides found in the U3 insertion RNA stretch (Li et al., 2011a) , namely C, G, A and U, respectively. In addition, a G at position 2 and a C at position 1 were also permitted for infectious culture (Fig. 1b) .
The miR-122 binding site 2 (S2) sequence is CACUCC (nt 37-42 in the HCV 2a genome), corresponding to the miR-122 seed nucleotide positions 7-2. S2 has been shown to play a subdominant role in HCV replication relative to S1 (Jangra et al., 2010) . We showed previously that the S2_A6G mutation was maintained after the first passage and was sensitive to the miravirsen treatment at a level equivalent to the WT virus (Li et al., 2011a) . To investigate whether mutations at each S2 position are permitted for infectious culture, here we changed each nucleotide of the miR-122 S2 into any of the three other nucleotides and tested the viability of the mutant recombinants in Huh7.5 cells (Table 3) . After RNA transfection, S2 mutant cultures C7A and C7G were 35 and 60 % HCV infected and mutants C5A, C5U, C5G and C3A had only few positive cells, whereas all other recombinants had 1-10 % HCV-positive cells on day 1. Sequence analysis of first-and second-passage S2 mutant viruses revealed that C7A, C7G, A6G and C2G were completely maintained, with peak infectivity titres of 10 4.4 -10 4.7 f.f.u. ml
, whereas A6U was maintained in the first passage but partially reverted in the second passage. We found previously that combination of mutations U4C/C3G/C2A in the S1 (designated S1_432CGA) was maintained after the first passage and conferred moderate resistance to miravirsen (Li et al., 2011a ); thus, we tested 432CGA mutations in S2 (designated S2_432CGA). The S2_432CGA showed 10 % HCV infection on day 1 and maintained all mutations after the second passage, producing supernatant HCV infectivity titres of 10 4.9 f.f.u. ml À1 (Fig. 1b and Table 3 ).
The J6
5¢UTR-NS2 /JFH1 mutants containing mutations in S1 or S2 after the second passage were tested for their sensitivity to miravirsen (Fig. 2b, c) . In Huh7.5 cells transfected with 0.4 nM miravirsen, the resistant mutant Cell-U3 had 67-71 % HCV-positive cells and the WT virus had 7-17 % compared with the mock. The mutants S1_C2G and S1_G1C had 40 and 26 % positive cells, respectively, and each was similar to S1_C2A (30 %) and S1_G1U (23 %), which we tested previously (referred to as mC2A and mG1U in Li et al., 2011a) . In addition, we also included S1_U4C (named mU4C in Li et al., 2011a) in the treatment, and it had 57 % HCV-positive cells, similar to 46-50 % observed previously (Fig. 2b) . The S2_432CGA had 67 % HCV-infected cells and S2_C2G was 28 %, while S2_C7A, S2_C7G, and S2_A6G were 9-16 % (Fig. 2c) . Taken together, these results suggested that the permissive single mutation in S1, as well as combined S2 mutations, conferred partial resistance to the antiviral effect of miR-122 antagonism. The mutations that conferred virus resistance to miravirsen treatment have been summarized in Fig. 1 
(d).
HCV recombinants with mutations in both S1 and S2 are highly resistant to miravirsen As mutations in S1 or S2 resulted in virus resistance to miravirsen (Fig. 2a, c) , we further studied the combination of mutations in these binding sites. We tested S1S2_A6G (S1_A6G plus S2_A6G), S1S2_C5U, S1S2_U4C, S1S2_C2A, S1S2_C2G and S1S2_432CGA, as well as S1_C7G+S2_A6G (Table 4 ). We previously found that while S1_A8G/ 4321CGAU mutations were maintained after passage to naïve cells, the downstream nucleotides CCA (positions 29-31) were deleted (Li et al., 2011a) . Thus, we also tested a mutant with S1_A8G plus S2_432CGA, designated S1_A8G +S2_432CGA. In addition, we constructed S1_A8G plus S1S2_432CGA and deletion of the GCCAU stretch between S1 and S2 (DGCCAU, the 'CC' of 'GCCAU' between S1 and S2 is involved in miR-122 binding; Machlin et al., 2011) , designated S1_A8G+S1S2m (Fig. 1e) . After transfection of Huh7.5 cells, S1_A8G+S2_432CGA culture was not HCV end of viral genome (5¢E) (a), miR-122-binding site 1 (S1) (b), miR-122 binding site 2 (S2) (c), and both S1 (e) and S2 (f). WT J6 5¢UTR-NS2 /JFH1, Cell-U3 and Cell-U3/InsG were included as controls. The percentage of virus infection by f.f.u. counts was relative to the respective infection in mock controls. The mean ± SEM of triplicate experiments is shown. *, The transfection virus was 5¢E_C3U/D4, which changed after passages, and thus was renamed 5¢E_C4U to fit with the nomenclature used; **, the transfection virus was 5¢E_InsCC, with only one C maintained after passages, and thus was renamed 5¢E_InsC; #, the second-passage-recovered S1_A8G+S1S2m virus ('m' indicates S1S2_432CGA+DGCCAU) that was used for treatment contained an A8C change in S1, and thus had a 5¢UTR sequence identical to S1_A8C+S1S2m shown in (e). Table 2 . Mutational analysis of the miR-122 binding site 1 (S1) of the HCV genome S1 corresponds to nt 21-27 (ACACUCCG) of the J6 5¢UTR-NS2 /JFH1 genome, corresponding to the miR-122 seed sequence positions 8-1. We previously tested recombinants with S1 nucleotides mutated to U3 RNA insertion or other nucleotides (Li et al., 2011a) . Here, we changed the nucleotides of S1 into the nucleotides that had not been tested previously. The underlined nucleotides indicate the introduced mutation(s). Two letters separated by a slash in parentheses indicate quasispecies of nucleotides observed in sequencing (capital/capital letters, nucleotides in 50 : 50 ratio; capital/lower case, nucleotides in dominant/minor pattern). ND, Not done; the second passage was not performed for the recombinants where the introduced mutation(s) reverted to WT after the first passage; -, immunostaining was not performed for cultures at day 1 post-transfection. positive until day 3, and S1S2_C3G, S1S2_C2G and S1S2_432CGA had 5 % HCV-infected cells on day 1, whereas the remaining S1S2 mutants showed 1 % HCVinfected cells on day 1 (Table 4) .
Supernatants collected from peak infection of transfection cultures were passaged to naïve Huh-7.5 cells. Sequence analysis of the first-and second-passage-recovered viruses revealed that S1S2_C2G, S1S2_432CGA and S1_A8G +S2_432CGA maintained all the mutations introduced and produced infectivity titres of 10 4.7 -10 5.0 f.f.u. ml À1 (Table 4) ; however, S1_A8G+S2_432CGA developed into a mixture of viruses with insertion of one, two or three Cs in the 5¢E region (Table 4 ). The S1_A8G of S1_A8G+S1S2m was changed to S1_A8C, but other mutations were maintained; for consistency, this second-passage-recovered virus was named S1_A8C+S1S2m in the treatment assays (Fig.  1f) . For the remaining S1S2 mutant viruses tested, mutations introduced in S1 or S2, or in both sites, reverted to WT nucleotides ( Fig. 1b and Table 4 ).
We hypothesized that the S1_A8G fi S1_A8C change may account for the increased infectivity of second-passage S1_A8G+S1S2m virus, which spread to most of the culture cells within 6 days and had a supernatant HCV infectivity titre of 10 5.0 f.f.u. ml À1 (Table 4) . We thus constructed and tested S1_A8C+S1S2m recombinant (Fig. 1f) . In two transfection cultures, S1_A8C+S1S2m spread to peak infection within 9 and 13 days, whereas the original S1_A8G+S1S2m reached peak infection at 33 and 35 days, suggesting that the change to S1_A8C improved the viability. S1_A8C+S1S2m maintained all the mutations after the second passage and reached infectivity titres of 10 4.6 f.f.u. ml À1 .
In cultures treated with 0.4 nM miravirsen, the resistant mutant Cell-U3 virus showed~100 % HCV-infected cells compared to the mock control. S1S2_C2G, S1S2_432CGA, S1_A8G+S2_432CGA and S1_A8C+S1S2m were highly resistant, all with >80 % HCV infected cells (Fig. 2d, e) , greater than other mutants with mutations only in S1 or S2. The S1S2_432CGA was~2-fold more resistant than S2_432CGA in the treatment assay (Fig. 2c, e) . Taken together, combinations of mutations in S1 and S2 confer a higher degree of virus resistance to miravirsen treatment (Fig. 1d) .
Further adaptation of host RNA insertion variant Cell-U3 highly resistant to miR-122 antagonism treatment
We found previously that substitution of SLI and S1 by a small nucleolar RNA (snoRNA) U3 fragment conferred virus resistance to miravrisen treatment (recombinant named Cell-U3, Fig. 1c ) (Li et al., 2011a) , and Cell-U3 has been used as a control in miR-122 antagonism assays ( Fig. 2 and Li et al., 2011a) and in high-throughput sequencing and cross-linking immunoprecipitation experiments (Luna et al., 2015) . However, Cell-U3 was attenuated and only produced infectivity titre of~10 3 f.f.u. ml À1 (Li et al., /JFH1 was not passaged in this study. However, previous studies showed that no mutations were found in the 5¢UTR sequence after viral passage (Li et al., 2011a) . †Experimental data from recombinants tested previously are included for comparison, but only the first passage was performed for these viruses; S1_C7G was from day 28 post-transfection and reverted to the WT sequence (Li et al., 2011a) . ‡Transfection and first virus passage were performed in two independent experiments. /JFH1 was not passaged in this study. However, we previously found that no mutations appeared in the 5¢UTR sequence after viral passage (Li et al., 2011a) . †Transfection and first virus passage were performed in two independent experiments. ‡This virus was constructed and tested previously, and mutation A6G was maintained in the first passage and did not confer virus resistance to miravirsen treatment (Li et al., 2011a) . In this study, we analysed the sequence of second-passage.
2011a). Here, we passaged Cell-U3 from a new transfection and identified a second-passage virus with an increased infectivity titre of 10 4.3 f.f.u. ml
À1
. Sequence analysis revealed that the recovered virus acquired a G insertion, causing the change of GCACCGAU (U3 RNA stretch replacing the S1 sequence) to GGCACCGAU. We engineered the G into Cell-U3 to generate the recombinant Cell-U3/InsG (Fig. 1c) . In transfection, Cell-U3/InsG showed 10 % infected cells on day 1 and spread to most of the culture cells by day 5 with infectivity titres of 10 4.0 f.f.u. ml
. Cell-U3/InsG maintained the introduced G after a second passage (10 4.4 f.f.u. ml
) and showed resistance to miravirsen treatment at a level similar to Cell-U3 (Fig. 2e) .
DISCUSSION
In this study, we systematically analysed the permissiveness of mutations in the miR-122 binding sites S1 and S2 in the HCV 5¢UTR domain I for viability in infectious cell culture, and the potential of such mutations in conferring virus resistance to the antiviral effect of miravirsen-mediated miR-122 antagonism. By individually mutating the nucleotides in S1, S2 or both, we were able to recover viruses that maintained mutations after the first and second passages in naïve Huh7.5 cells. The sequence at the 5¢E required the four nucleotides ACCC for optimal function; mutations replacing the second nucleotide C were not permitted or they reverted, while G or A replacing the third C nucleotide were permitted. Single-nucleotide changes were permitted in specific sites of the S1 or S2 sequence, and combined mutations of C, G and A at positions 4, 3 and 2 (referred to as 432CGA) were permitted in S1, S2 or both sites. C2G in both S1 and S2 was also permitted. The permissive 5¢E mutations did not confer virus resistance to miravirsen treatment, and single mutations in S1 and S2 conferred a low level of virus resistance, while combined mutations involving both S1 and S2 induced a high degree of virus resistance to miravirsen treatment.
Increasing evidence suggests that increased miRNA expression, miRNA-target interaction and networks might contribute to disease processes, including genetic and infectious diseases as well as cancer (Hrdlickova et al., 2014) . With increasing knowledge of miRNAs in a variety of diseases, the approach targeting host miRNAs has emerged as an interesting therapeutic strategy. miR-122 is the most abundant miRNA in the human liver and plays an important role in liver biology and disease. The miR-122 inhibitor miravirsen was the first miRNA-based molecule to enter clinical trial, providing proof of concept for the potential of miravirsen as a novel drug against chronic HCV infection (Janssen et al., 2013) , and thus representing an example of a new type of antiviral that might have relevance for other infectious diseases.
Studies have demonstrated that miravirsen has broad antiviral activity and a relatively high genetic barrier to resistance (Janssen et al., 2013; Lanford et al., 2010) . Previously, we discovered that introducing mutations in S1 or substituting both SLI and S1 with a host U3 snoRNA fragment conferred virus resistance to miravirsen treatment (Li et al., 2011a) , thus indicating that virus escape could potentially occur in HCV patients during miravirsen-based therapy. Recently, HCV rebound in an HCV patient observed after completion of miravirsen clinical phase II trial was found to be associated with mutation C3U in the 5¢E involved in miR-122 binding (Ottosen et al., 2015) . However, this finding could not be confirmed in vitro, as the 5¢E_C3U virus reverted to the WT sequence in our study (Table 1) . Also, we found that permissible mutations in the 5¢E did not confer resistance to miravirsen. However, the identification of permissive mutations in S1 and S2, and their association with virus resistance to miravirsen treatment, are highly relevant for clinical studies. These findings will also facilitate the study of additional functions of miR-122 in the HCV life cycle.
Through mutational analysis of each nucleotide in S1 and S2, we found that only a few single nucleotides in the miR-122 binding sites were permissive after the second passage of transfection-recovered viruses. HCV with single mutations conferred a low level of virus resistance to miravirsen (Fig. 2b, c) , suggesting that these viruses are still dependent on miR-122. A recent study showed that HCV recombinant Jc1 with a G1A change in the S1 site (G28A in the genotype 2a genome) was selected from miR-122-antagonized Huh7.5 cells and was responsible for virus resistance to miR-122 inhibition (Israelow et al., 2014) . We here tested G fi A, G fi U and G fi C changes at position 1 of the S1 and found that these mutations did not appear to affect the replication of the virus, with a high percentage of infected cells on day 1 post-transfection (Table 2 and Li et al., 2011a) . However, only S1_G1U (Li et al., 2011a) and S1_G1C (Table 2) were maintained in first-and second-passage viruses, respectively, and conferred partial resistance to the miravirsen treatment (Fig. 2b, c) , whereas S1_G1A reverted in the first passage. The discrepancy in S1_G1A results between our study and Jc1-based selection are probably due to the differences in the genome used and the experimental approach. We used J6 5¢UTR-NS2 /JFH1, which contained the entire 5¢UTR-NS2 region from the J6 strain (Li et al., 2011a) , while Jc1 contains the 5¢UTR of JFH1 and the core-NS2 domain I from J6 (Pietschmann et al., 2006) ; thus, to address this discrepancy, further investigation may be required.
Although single mutations in S1 and S2 only led to a low level of resistance to miravirsen treatment, combination of permissive mutations in both the S1 and S2 sites conferred a higher level of virus resistance to miravirsen treatment (Fig. 2d, e) . Interestingly, nucleotides CGA found in the U3 snoRNA insertion were permitted in S1, S2 or both (Table 4 ), and conferred high-level virus resistance to miravirsen treatment. Mutant viruses with S1S2_C2G, with other mutations plus 432CGA in either S1S2 or S2, or with S2_432CGA were all highly resistant to miravirsen treatment, comparable to the level of resistance that Cell-U3 viruses created (Fig. 2c, e) . The Cell-U3 virus was recently shown to be independent of miR-122 for replication; Table 4 . Mutational analysis of S1 and S2 of the HCV genome S1 and S2 correspond to nt 21-27 (S1, ACACUCCG) and [37] [38] [39] [40] [41] [42] CACUCC) /JFH1 virus was not passaged in this study. However, previous studies showed that no mutations were found in the 5'UTR sequence after viral passage (Li et al., 2011a) . †Transfection was performed in two independent experiments. ‡Analysis of eight clones revealed that the 5'E of this virus was changed from ACCCG to ACCCCCCG, ACCCCCG and ACCCCG in two, three and three clones, respectively. §'m' indicates S1S2_432CGA+?DGCCAU. ||Peak infectivity titre of 10
at day 18 post-transfection.
however, its replication could be increased by the presence of miR-122 (Li et al., 2011a; Luna et al., 2015) . These miravirsen-resistant mutant HCVs might depend on other unknown host factors or on the changed stem-loops permitting HCV growth in Huh7.5 cells without miR-122. Thus, it would be of interest to study the mechanism of miR-122-independent replication of HCV recombinants.
Virus resistance to treatment is a major concern for HCV drug development. Miravirsen has demonstrated broad antiviral activity against various genotypes of HCV (Li et al., 2011a) , and no evidence of virus resistance was originally identified in HCV-infected chimpanzees after miravirsen treatment (Lanford et al., 2010) or in patients in clinical phase II trials (Janssen et al., 2013) . As mentioned above, the 5¢E mutation C3U emerged in a miravirsen-treated HCV patient, but the virus was still fully susceptible to other direct-acting agents (DAAs) (Ottosen et al., 2015) ; thus, HCV that escaped from miravirsen treatment could be treated by DAAs. This observation suggests that a combination of miravirsen and DAAs may create a higher genetic barrier preventing virus escape from treatment.
The nucleotides involved in the miR-122 binding sites are highly conserved across genotypes [ (Lanford et al., 2010) and the Los Alamos hepatitis C sequence database (http:// hcv.lanl.gov/content/index)], and we have demonstrated previously that HCV genotypes 1-6 are all dependent on miR-122 for efficient infection (Li et al., 2011a) . Theoretically, mutations in the miR-122 binding sites of the HCV genome will disrupt miR-122 binding to viral RNA, and thus replication of such mutant HCVs may not rely on miR-122. Identification of single or combined mutations replacing the conserved miR-122 binding nucleotides has expanded our study towards an understanding of the additional roles of miR-122 in the complete HCV life cycle. The identified miR-122 site mutant HCVs will be useful tools for the studies of virus escape from miR-122-antagonized therapy.
METHODS
Plasmids. The HCV genotype 2a recombinant J6 5¢UTR-NS2 /JFH1 and Cell-U3 plasmids were constructed previously (Li et al., 2011a) . Mutations in the miR-122 binding sequence were chemically synthesized (GenScript) or generated by site-directed mutagenesis PCR and subsequently constructed into the J6 5¢UTR-NS2 /JFH1 using standard cloning procedures. The entire HCV sequence of final plasmid preparations was confirmed (Macrogen).
Transfection, viral passage and infectivity titre in Huh7.5 cells.
The human hepatoma cell line Huh7.5 was maintained in Dulbecco's Modified Eagle Medium (DMEM) (Themo Fisher Scientific) supplemented with 10 % FBS (Sigma) and ampicillin/streptomycin (0.5 mg ml
À1
; Thermo Fisher Scientific) at 37 C and 5 % CO 2 , as described previously (Gottwein et al., 2007; Lindenbach et al., 2005) . At 24 h prior to transfection or infection, 3.5 Â 10 5 cells per well were seeded in six-well plates. For transfection experiments, 10 µg HCV recombinant plasmid DNA was linearized with XbaI and treated with mung bean nuclease (New England Biolabs). Purified DNA was in vitro transcribed into HCV RNA transcripts using T7 RNA polymerase (Promega) in a reaction volume of 100 µl and transfected using Lipofectamine 2000 (Thermo Fisher Scientific) as described previously (Li et al., 2012a) . The transfected cultures were left for~16 h, trypsinized and seeded into fresh culture flasks. The cultures were then subcultured every 2-3 days. HCVpositive cells were monitored by immunostaining for HCV NS5A antigen using mAb 9E10 (Lindenbach et al., 2005) . When the proportion of HCV-positive cells reached ! 80 % of cultured cells (peak infection), the culture supernatant was collected, filtered (0.45 m) and stored at À80 C. To perform first-passage experiments, naïve Huh7.5 cells in sixwell plates were incubated with 1 ml transfection-derived culture supernatant for~16 h, and the cultures were then subcultured every 2-3 days. Virus collected at peak infection was designated first-passage virus. To perform second-passage experiments, virus from peak infection of the first passage was inoculated onto naïve Huh7.5 cells and supernatants were collected at peak infection to generate second-passage virus. HCV infectivity titres in the culture supernatant were determined by f.f.u. assay as described previously (Gottwein et al., 2010; Scheel et al., 2011) . Primary mAb 9E10 against HCV NS5A antigen was used in 1 : 1000 dilutions, and the number of f.f.u. was counted automatically by an ImmunoSpot Series 5 UV Analyser with customized software (CTL Europe GmbH) (Gottwein et al., 2010) . The viral infectivity titre is presented as f.f.u. ml -1 supernatant from three independent dilutions.
5¢ RACE. 5¢ RACE (Invitrogen) with dC or dA tailing technology was used to analyse the 5¢UTR of recovered HCV, as described previously (Li et al., 2011a, b) . Briefly, RNA was extracted from 200 µl culture supernatant using TRIzol LS Reagent (Invitrogen). The RNA was denatured at 70 C for 10 min, and cDNA was synthesized at 42 C for 30 min with SuperScript II reverse transcriptase (Invitrogen). The HCV genotype-specific primers for RT-PCR have been described previously (Li et al., 2011a) . The PCR products were sequenced directly or cloned into pCR2.1-TOPO (Invitrogen) for sequence analysis.
Miravirsen treatment. Miravirsen were synthesized by Exiqon (5¢-CcAttGTcaCaCtCC-3¢; LNA in capitals, DNA in lower case, complete phosphorothioate backbone; capital C denotes LNA methylcytosine) (Lanford et al., 2010; Li et al., 2011a) . The miravirsen treatment experiments have been previously described in detail (Li et al., 2011a) . Briefly, Huh-7.5 cells were seeded in Nunc 96-well optical bottom plates (6 Â 10 3 cells per well) for 16 h. The cells were transfected with miravirsen at the given concentrations using Lipofectamine 2000 (Invitrogen), incubated for 10 h, and then retransfected with miravirsen and incubated for another 14 h. The transfected cells were then infected with mutant viruses, in parallel with WT virus and Cell-U3 virus as controls. The cells were incubated for 48 h, and the cells were then fixed and immunostained for HCV NS5A, and analysed for f.f.u. counts, as described previously (Li et al., 2011a) .
